MAPT and Alzheimer disease: 18F-AV-1451 positive results can also be observed in preclinical AD patients, with faster increase of tracer retention being observed in the group of high amyloid burden [150], which may further suggest a close relationship between tau and amyloid-beta, making 18F-AV-1451 PET a valuable method to screen and determine subjects in disease-modifying clinical trials.